Biogen Aktie News

NEW YORK , May 23, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. ("Biogen Inc." or "the Company") (NASDAQ: BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the...

NEW YORK--(BUSINESS WIRE)---- $BIIB #Investigation--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Colorado on behalf of those who acquired Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) securities during the period of February 3, 2022 through February 13, 2024, inclusive (“the Class Period”). Inves...

NEW YORK--(BUSINESS WIRE)---- $BIIB #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violation...

LOS ANGELES , May 23, 2024 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who pur...

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements re: Biogen business and prospects, resulting in its stock trading at inflated prices.

Biogen (BIIB) announced Wednesday it had purchased privately-held Human Immunology Biosciences (HI-Bio) for at least $1.15 billion to expand its reach into immunology medicines.

NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the"Company") (NASDAQ: BIIB) and certain officers. The class action, filed in the United States District Court for the District of Colorado, and docketed under 24-cv-01444, is on behalf of a class consisting of all persons and entities other than Defendants...

Biogen Inc. BIIB, -1.68% said Wednesday it's acquiring privately held Human Immunology Biosciences for $1.15 billion upfront and up to $650 million in potential milestone payments in a move aimed at bolstering its immunology portfolio. Hi-Bio's lead asset felzartamab is a fully human anti-CD38 monoclonal antibody that has shown clinical proof of concept in treating rate immune-mediated indicati...